POSTER SESSION II Monday, March 8, 2004   —  1:00 - 4:30 PM Exhibit Hall B and C BREAST PATHOLOGY 13 A Comparison of Quantitative Immunohistochemistry and Chromogenic In-Situ Hybridization for the Assessment of HER-2/neu in Breast Cancer (101) RR Dalton, SC Peiper, RB Hessler - Medical College of Georgia, Augusta, GA 14 Comparison of Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) in the Evaluation of HER-2 Status (120) Y Gong, L Diaz, E Tarco, E Wiley, N Sneige - UT M.D. Anderson Cancer Center, Houston, TX; The Feinberg School of Medicine, Northwestern University, Chicago, IL 15 A New Anti-HER2 Monoclonal Antibody (Nichirei SV2-61g): The Best Concordance with HER2 FISH (206) S Umemura, Y Kitano, H Ohbayashi, M Takenaga, RY Osamura - Tokai University School of Medicine, Isehara, Kanagawa, Japan; Biosciences Research & Development Center, Nichirei Corporation, Higashimurayama, Tokyo, Japan 16 SILVERFISH A Novel Bright-Field Assay for Simultaneous Detection of HER2 Gene Amplification and Protein Expression Predicts Clinical Outcome in Invasive Breast Cancer (128) D Hicks, M Skacel, E Downs-Kelly, M Cheang, J Pettay, FD Hsu, TO Nielsen, J Mele, DG Huntsman, R Powell, J Hainfeld, T Grogan, R Tubbs - Cleveland Clinic Foundation, Cleveland, OH; University of BC, Vancouver, Canada; Nanoprobes, Yaphank, NY; Ventana Medical Systems, Tucson, AZ 17 Incidence of Topoisomerase II-alpha (TOP2A) Co-Amplification and Deletion in Adenocarcinoma of the Breast with HER2 Gene Amplification (129) DG Hicks, M Skacel, GT Budd, M Hartke, J Pettay, RR Tubbs - Cleveland Clinic Foundation, Cleveland, OH 18 Analytical Validation of SILVERFISH, a Bright Field Second Generation Autometallographic Assay for Concomitant Detection of HER2 Gene Amplification and Encoded Protein Expression (205) R Tubbs, J Pettay, M Skacel, E Downs-Kelly, D Hicks, R Powell, P Roche, T Grogan, J Mele, J Hainfeld - Cleveland Clinic Foundation, Cleveland, OH; Nanoprobes, Yaphank, NY; Ventana Medical Systems, Tucson, AZ 19 Ariol™ Image Analysis of HER-2/neu Status of Invasive Breast Cancer (125) SR Hasan, LP Howell, BM Ljung, KW Nowels, DC Oates, N Pavlak - Applied Imaging Corp., Santa Clara, CA; University of California, Davis School of Medicine, Davis, CA; University of California, San Francisco, San Francisco, CA; Stanford University, Palo Alto, CA 20 Biological Tumor Characteristics Can Predict HER-2/neu Status in Breast Cancer: Detailed Results and Utility of Quality Assurance Program on a Cohort of 3500 Patients 212 H Yaziji, LC Goldstein, TS Barry, AW Hing, HM Hwang, RW Werling, AM Gown - PhenoPath Laboratories and Immunocytochemistry Research Institute of Seattle, Seattle, WA 21 HER 2/neu Expression and Gene Amplification in Tubular Carcinoma of the Breast (98) L Cooper, C Morrison - Ohio State University Medical Center, Columbus, OH 22 Predictive Factors for Response To Herceptin® in HER-2 Overexpressing Locally Advanced Breast Cancer (LABC) (164) SK Mohsin, H Weiss, SG Hilsenbeck, C Gutierrez, CK Osborne, DC Allred, J Chang - Breast Center, Baylor College of Medicine, Houston, TX 23 HER-2/neu Expression in Breast Carcinomas: Pre- and Post-Treatment to Neoadjuvant Chemotherapy (178) MR Quddus, CJ Sung, C Zhang, M Eklund, T Pasquariello, MM Steinhoff - Women & Infants Hospital and Brown Medical School, Providence, RI 24 Biopsy Method Collection Comparison of a Gene Expression Profile Based Prediction of Complete Pathologic Response to Neoadjuvant TAXOL/FAC Chemotherapy in Breast Cancer (196) J Stec, JS Ross, L Pusztai, M Ayers, J Metivier, E Clark, G Linette, N Sneige, V Valero, K Hess, GN Hortobagyi, A Damokosh, WF Symmans - Millennium Pharmaceuticals, Inc, Cambridge, MA; Albany Medical College, Albany, NY; Univ Texas, MD Anderson Cancer Center, Houston, TX 25 Topoisomerase II Expression and Not HER2 or p53 Is a Predictor of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Locally Advanced Primary Breast Carcinomas (112) PL Fernandez, M Martin-Richard, M MuZoz, J Albanell, L Colomo, MJ Rey, J Tabernero, C Alonso, A Cardesa, P Gascon, E Campo - Hospital Clinic and IDIBAPS, Barcelona, Barcelona, Spain; Hospital San Pau, Barcelona, Barcelona, Spain 26 Correlation of Anthracycline-Based Neoadjuvant Chemotherapy Response with c-erb-B2 Amplication by Fluorescence In Situ Hybridization (FISH), and Other Prognostic Indicators in Locally Advanced Breast Carcinoma (148) H-C Lee, JO Lee, SY Cho, IA Park - Seoul National University Hospital, Seoul, Korea 27 Overexpression of the HER2 Gene in Breast Cancer in Young Women: A Study from Northern Thailand (91) B Chaiwun, C Ya-in, S Lekawanvijit, J Settakorn, Y Jiviriyawat, M Ho, S Rangdaeng, PS Thorner - Chiang Mai University, Chiang Mai, Thailand; Hospital for Sick Children, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada 28 Differential Expression of HER-2/neu Receptor of Invasive Mammary Carcinoma between Caucasian and African American Patients in the Detroit Metropolitan Area. Correlation with Overall Survival and Other Prognostic Factors (74) MA Al-Abbadi, TA Washington, SE Tekyi-Mensah, HA Saleh, DR Lucas, CA Briston - Sinai-Grace Hospital and Karmanos Cancer Institute - Wayne State University, Detroit, MI 29 Molecular Evaluation for Herceptin® Binding Site Mutations in HER-2 Positive Invasive Breast Cancer (167) WD Mojica, T Khoury, RT Cheney - The State University of New York at Buffalo, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY 30 Analysis of Intratumoral Heterogeneity and Amplification Status in Weakly (2+) HER-2/neu Positive Breast Carcinomas (150) JT Lewis, C Reynolds, RB Jenkins, DW Visscher - Mayo Clinic, Rochester, MN